We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Xyphos

News List

United Immunity and Xyphos, an Astellas Company, to Collaborate on Next Generation Nano-Immunotherapies for Cancer Treatment prnasia
January 15, 2021
United Immunity, Co., Ltd. has entered into a joint research agreement as of December 2020 with Xyphos Biosciences, Inc., (California, US), a subsidiary of Astellas Pharma Inc. (Tokyo, Japan).
Astellas has announced its acquisition of Xyphos for $665m europeanpharmaceuticalreview
January 09, 2020
Xyphos Biosciences will become a wholly owned subsidiary of Astellas Pharma following an acquisition made by the latter company.
Astellas Acquires Xyphos Biosciences americanpharmaceuticalreview
January 06, 2020
Astellas Pharma announced the company has acquired Xyphos Biosciences. With the acquisition Astellas will gain Xyphos' novel and proprietary ACCEL (Advanced Cellular Control through Engineered Ligands) technology platform.